Cytokinetics, Incorporated

BIT:1CYTK Stock Report

Market Cap: €9.7b

Cytokinetics Management

Management criteria checks 3/4

Cytokinetics' CEO is Robert Blum, appointed in Feb 2006, has a tenure of 20.33 years. total yearly compensation is $11.88M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth €16.63M. The average tenure of the management team and the board of directors is 5.1 years and 13.3 years respectively.

Key information

Robert Blum

Chief executive officer

US$11.9m

Total compensation

CEO salary percentage7.18%
CEO tenure20.3yrs
CEO ownership0.2%
Management average tenure5.1yrs
Board average tenure13.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Robert Blum's remuneration changed compared to Cytokinetics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$830m

Dec 31 2025US$12mUS$853k

-US$785m

Sep 30 2025n/an/a

-US$752m

Jun 30 2025n/an/a

-US$606m

Mar 31 2025n/an/a

-US$615m

Dec 31 2024US$14mUS$820k

-US$590m

Sep 30 2024n/an/a

-US$576m

Jun 30 2024n/an/a

-US$545m

Mar 31 2024n/an/a

-US$531m

Dec 31 2023US$9mUS$782k

-US$526m

Sep 30 2023n/an/a

-US$527m

Jun 30 2023n/an/a

-US$540m

Mar 31 2023n/an/a

-US$431m

Dec 31 2022US$9mUS$742k

-US$389m

Sep 30 2022n/an/a

-US$282m

Jun 30 2022n/an/a

-US$216m

Mar 31 2022n/an/a

-US$258m

Dec 31 2021US$6mUS$709k

-US$215m

Sep 30 2021n/an/a

-US$229m

Jun 30 2021n/an/a

-US$156m

Mar 31 2021n/an/a

-US$135m

Dec 31 2020US$5mUS$682k

-US$127m

Sep 30 2020n/an/a

-US$114m

Jun 30 2020n/an/a

-US$140m

Mar 31 2020n/an/a

-US$132m

Dec 31 2019US$3mUS$656k

-US$122m

Compensation vs Market: Robert's total compensation ($USD11.88M) is above average for companies of similar size in the Italian market ($USD3.82M).

Compensation vs Earnings: Robert's compensation has been consistent with company performance over the past year.

CEO

Robert Blum (62 yo)

20.3yrs
Tenure
US$11,881,456
Compensation

Mr. Robert I. Blum has been Chief Executive Officer, President and Director of Cytokinetics, Incorporated since January 22, 2007 and served as its Principal Financial Officer until May 08, 2024. Mr. Blum p...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Blum
CEO, President & Director20.3yrsUS$11.88m0.17%
€ 16.6m
Sung Lee
EVP & CFO2.1yrsUS$3.77m0.0016%
€ 154.5k
Jeffrey Hessekiel
Executive VPless than a yearUS$6.09mno data
Fady Malik
Executive Vice President of Research & Development14yrsUS$4.47m0.073%
€ 7.1m
Andrew Callos
Executive VP & Chief Commercial Officer5.3yrsUS$3.79m0.0012%
€ 113.7k
James Sabry
Co-Founder & Chairman of Scientific Advisory Board28.8yrsUS$41.50kno data
James Spudich
Co-Founder & Member of Scientific Advisory Board28.8yrsUS$21.94kno data
Jeff Lotz
Vice President of Sales & Operations4.8yrsno datano data
Holly Laughlin
VP of Accounting & Corporate Controller1.3yrsno datano data
Steven Cook
Senior Vice President of Global Supply Chain Operations & Technical Operationsno datano datano data
Scott Jordan
Senior Vice President of Global Marketing & Commercial Strategy5.1yrsno datano data
Isaac Ciechanover
EVP of Corporate Development & Chief Business Officer2yrsno datano data
5.1yrs
Average Tenure
62yo
Average Age

Experienced Management: 1CYTK's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Blum
CEO, President & Director19.4yrsUS$11.88m0.17%
€ 16.6m
James Sabry
Co-Founder & Chairman of Scientific Advisory Board18.2yrsUS$41.50kno data
James Spudich
Co-Founder & Member of Scientific Advisory Boardno dataUS$21.94kno data
B. Parshall
Independent Director13.3yrsUS$540.00k0.012%
€ 1.1m
Nancy Wysenski
Independent Director5.6yrsUS$501.34k0.025%
€ 2.4m
John Henderson
Independent Chairman17.3yrsUS$480.29k0.058%
€ 5.6m
John Lowe
Member of Scientific Advisory Boardno datano datano data
Thomas Pollard
Member of Scientific Advisory Boardno datano datano data
David Morgans
Member of Scientific Advisory Board9.9yrsUS$942.23kno data
Lawrence S. Goldstein
Member of Scientific Advisory Boardno datano datano data
John Solaro
Member of Scientific Advisory Boardno datano datano data
Muna Bhanji
Independent Director5.3yrsUS$520.75k0.019%
€ 1.9m
13.3yrs
Average Tenure
70yo
Average Age

Experienced Board: 1CYTK's board of directors are seasoned and experienced ( 13.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/25 18:02
End of Day Share Price 2026/06/25 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cytokinetics, Incorporated is covered by 37 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Emily FieldBarclays
Huidong WangBarclays